2014-03-31 12:19:04 - Intravenous (IV) Iron Drugs: A Global Strategic Business Report - a new market research report on companiesandmarkets.com
Global market for Intravenous (IV) Iron Drugs is projected to reach US$1.6 billion by 2018, driven by aging population, rising incidences of chronic kidney disease (CKD), increasing number of patients on dialysis, and unresponsive oral therapies in many patients.
The Intravenous (IV) Iron Drugs market is witnessing strong growth driven by widespread iron deficiency anemia as a result of diseases related to oncology, gynecology, gastroenterology and nephrology. Iron deficiency anemia (IDA) is recognized as a debilitating nutritional deficiency affecting approximately 2.0 billion individuals worldwide. The condition is particularly high in patients suffering from Chronic Kidney Disease (CKD), a condition which is increasingly becoming a burden to healthcare systems worldwide.
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.